



DISCLAIMER

This investor presentation (Presentation) is dated 28 November 2022 and has been prepared by Bubs Australia Limited (ACN 060 094 742) (Bubs or the Company). The material in this Presentation is general background information about Bubs' activities current at the date of the Presentation. It has been prepared based on information available to it, including information from third parties, and has not been independently verified nor does it purport to be complete. No representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the information or opinions contained in this Presentation.

This Presentation does not constitute investment or financial product advice (nor taxation, accounting or legal advice) and does not take into account the investment objectives, financial situation or needs of any particular investor. It is not a prospectus, product disclosure statement or other disclosure or offering document under Australian law or any other law. This Presentation is not and should not be considered a recommendation to, or offer or an invitation to acquire shares in Bubs, nor does it form the basis of any contract or commitment for the acquisition of shares. The distribution of this Presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions.

This Presentation contains certain 'forward-looking statements'. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Bubs, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Bubs' business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Bubs, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward-looking statements are based on information available to Bubs as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), none of Bubs, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements

Certain non-IFRS financial information has been included to assist in the making appropriate comparisons with prior periods to assess the operating performance of the business. Bubs uses these measures to assess the performance of the business and believes that the information is useful to investors. Non-IRFS information has not been subject to auditor review.

Unless otherwise stated, all dollar values are in Australian dollars (\$ or A\$). A number of figures, amounts, percentages, estimates, calculations of value and fractions in this Presentation are subject to the effect of rounding.

























Creating new generations of happy & healthy

Goodness

We believe in wholesome, healthy food and a positive approach to life



Very Best

We believe in being thorough and uncompromising, sticking to our ethics no matter what



Honesty

We believe in
100% transparency,
this is 'clean' food
from a brand
you trust



Playfulness

We believe in joy of family time, pleasure of sharing happy moments and being together





Chair Welcome 08

CEO Address 11

Formal Business 22

Shareholder Q&A 34





bübs

CHAIR WELCOME



Dennis Lin Executive Chairman









soth lian ards

Bubs Australia awarded 2022 Australian Exporter of the Year



alian Trade and Investment Commission



60th

Australia












HOW TO ASK A QUESTION


- To ask a written question select the Q & A icon
- Select the topic your question relates to from the drop-down list
- Type your question in the text box and press the send button
- To ask a verbal question follow the instructions below the broadcast window.





HOW TO VOTE

- When the poll is open, select the vote icon at the top of the screen
- To vote, select either For, Against or Abstain
- You will see a vote confirmation
- To change or cancel your vote "click here to change your vote" at any time until the poll is closed





OUR BOARD: BENCH STRENGTH FOR FUTURE GROWTH

Supporting future business needs with expertise in global growth, consumer brands, dairy operations and capital markets.

BOARD OF DIRECTORS



DENNIS LIN Executive Chairman

- China & global growth expert
- M&A specialist
- Accountant & Lawyer
- Extensive ASX Board & Governance experience



KRISTY CARR
Managing Director

- Founder since 2006
- International business development
- Growth marketing
- Infant nutrition specialist



KATRINA RATHIE

Non-Executive Director

- Leading expert in international IP law
- Remuneration & Nomination
- FMCG brand specialist
- NED SBS & Starlight Children's Foundation



STEVE LIN
Non-Executive Director

- Expertise across Asia & USA
- International investments
- Corporate management



JAY STEPHENSON
Company Secretary

 Extensive professional Company Secretary experience for ASX companies

KEY MANAGEMENT PERSONNEL'



RICHARD PAINE
Chief Operating Officer

- Dairy operations & supply chain
- Nutritional manufacturing specialist



IRIS REN
Chief Financial Officer

- Financial advisory & corporate transactions
- Audit & compliance

bübs.

CEO ADDRESS



Kristy CarrFounder & CEO



FY22 STRATEGIC OVERVIEW

Bubs milestone achievements delivered record revenue in FY22 with a shift to earnings growth profile.

FY22 FINANCIAL ACHIEVEMENTS



Record Revenue

Return to high growth trajectory more than double prior year



Positive Underlying EBITDA¹

Delivery of first profit, excluding non-cash compensation expense



Gross Margin Improvement

Significant groupwide gains and optimised product and channel mix

FY22 STRATEGIC MILESTONES





High Growth in Domestic Retail Scan Sales and Market Share

Record sales and market share gains No.1 Goat Formula brand in Australia²





China Channel Strategic Partnership

China revenue at a record high with roll out of innovative M2C model commencing











USA Ranging in >6,000 stores across 42 States

540,000 tins of Bubs® Infant Formula chartered by U.S. Government under 'Operation Fly Formula'





INNOVATION: LAUNCH INTO A2 PROTEIN CATEGORY

Bubs comprehensive portfolio caters for different dietary needs across the three highest growth segments, with the identical products sold in Australian retailers being exported to China and USA.










Australia China USA

14



REGULATORY MILESTONES

Bubs is one of very few companies globally to establish a regulatory pathway for permanent full access into the two largest infant formula markets in the world for the first time.



Bubs is in the due diligence phase of finalising our joint venture agreements with China-based manufacturing and supply entities to secure approval of an existing SAMR brand slot with the intent of rebranding as Bubs® to launch a new GB compliant ultra-premium Goat formula range in General Trade.

Bubs is committed to meeting the requirements for permanent market access under the U.S. FDA Infant Formula Transition Plan for Exercise of Enforcement Discretion. Bubs® existing Australian product range already satisfies U.S. nutrient requirements and will continue to be imported until October 2025.



FINANCIAL HIGHLIGHTS

High growth global strategy delivers scale with record earnings, gross margin and revenue.

\$104.2m

Record Gross Revenue¹



Significantly improved Group Gross Margin \$4.8m

Underlying EBITDA profit 3

+177%

Infant Formula Revenue growth pcp +166%

China Revenue growth pcp

+39%

Domestic scan sales growth YOY Record market share² \$63m

Post balance sheet date successful completion of capital raise

¹ Gross revenue is a non-IFRS measure, Non-IFRS measures have not been subject to audit or review.

Gross revenue represents the revenue recognised without rebates and marketing contribution.

² IRI Scan Data, Dollars (\$000's) Growth YA, Coles, Woolworths and Chemist Warehouse combined to MAT 03/07/2022.


³ Underlying EBITDA profit \$4.8m is calculated as: EBITDA loss of \$7.8m, excluding share-based payments (\$8.3m) and equity linked transactions (\$4.2m) with strategic trading partner.

DELIVERING SCALE AND PROFITABLE GROWTH


Our long-term profitable growth is underpinned by continued product margin improvement and diversification of our product and channel mix.



Record Gross Revenue¹ **Underlying** FY22 EBITDA² \$104.2m \$4.8m 61.7 46.8 65.7 46.8 COVID Impact 33.0 24.6 25.8 38.5 28.8 22.2 21.0 FY19 FY20 FY21 FY22 ■ 1H ■ 2H



Diversification



¹ Gross revenue is a non-IFRS measure. Non-IFRS measures have not been subject to audit or review. Gross revenue represents the revenue recognised without rebates and marketing contribution.

² Underlying EBITDA profit \$4.8m is calculated as: EBITDA loss of \$7.8m, excluding share-based payments (\$8.3m) and equity linked transactions (\$4.2m) with strategic trading partner.

order tyring Ebir DA profit \$4.01113 catediated as. Ebir DA toss of \$7.0111, excluding share based payments (\$6.0111) and equity timed it ansactions (\$4.2111) with strategic trading particles.

³ Product margin is calculated as (Revenue – Production Costs) / Revenue. Revenue excludes Corporate Daigou equity linked transaction.

¹⁷



PRECISION PERFORMANCE GROWTH

GROUP STRATEGIC FOCUS

Omni-channel expansion in key markets through performance marketing that is driven by data and aligning brand values with consumer sentiments.



AUSTRALIA

 Grow market share through brand identity refresh and supporting parents through their baby feeding journey.

CHINA

- Focus on omni-channel strategy and rapid expansion of M2C driven by data – knowing where every tin is sold in China.
- Obtain SAMR registration and launch China label products in Mother and Baby stores.


USA


- Obtain FDA permanent approval by October 2025.
- Evolve brand storytelling and marketing strategies to engage and convert American millennial parents.
- Performance based growth marketing to maximise return on each marketing dollar.



AUSTRALIA: STRONG HOME MARKET IN HIGH GROWTH

Bubs Australia is the fastest growing infant formula manufacturer in Australia¹. Bubs[®] is the clear challenger brand, outperforming the category with high scan sales growth and strong market share gains.













CHINA: MANUFACTURER-TO-CONSUMER (M2C) MODEL

Leveraging re-engineered Daigou channel boosted by strategic partnership with AZ Global. Direct delivery from within China via reseller recruitment provides end-to-end channel movement visibility.











Fast growing brand power and targeted social community reach, combined with channel focused strategy, is leading to higher sales conversion and ROI.





Products delivered to homes without 3rd party touching the parcel: fast, reliable, transparent.





USA: FIRST MOVER ADVANTAGE

Speed to market has unlocked enormous value to quickly advance regulatory approvals, our retail distribution footprint and brand awareness, providing a strong foundation for long-term profitable growth.







SUMMARY

Bubs team demonstrated resilience, agility and focus throughout Financial Year 2022, delivering a strong strategic scorecard and record results.



We entered FY23 with:

- a diversified product portfolio in our most profitable business segment;
- a new growth horizon with the accelerated market access in the USA;
- a re-engineered M2C business model in China providing end-to-end channel visibility;
- permanent regulatory pathways for full access to the world's two largest infant formula markets; and
- a robust balance sheet to increase our manufacturing capacity and support our future growth plans.











bübs.

FORMAL BUSINESS





TABLE: COMPANY FINANCIAL STATEMENTS

To table the financial statements, directors' report and auditors' report for the Company for the year ended 30 June 2022. Shareholders are not required to vote or formally approve or adopt the financial reports.






Please note: The Annual Report 2022 is only available as electronic version. To access <u>click here</u>



OUR RESOLUTIONS

Voting will be closed shortly. Please ensure that you have cast your vote on all resolutions.





ADOPTION OF REMUNERATION REPORT

To adopt the remuneration report for the financial year ended 30 June 2022. In accordance with the Corporations Act, this resolution is advisory only and does not bind the company or the directors.



"That, for the purpose of Section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report, as contained in the Company's annual financial report for the financial year ended 30 June 2022."

PROXY TYPE	NUMBER	%
For	147,313,980	78.01
Against	39,190,594	20.75
Open-usable	2,338,080	1.24
Abstained	586,806	N/A
Total	189,429,460	100



RE-ELECTION OF DIRECTOR MR DENNIS LIN

To consider and, if thought fit, to pass the following resolution as an ordinary resolution of the Company:



"That for the purpose of Clause 14.2 of the Constitution, ASX Listing Rule 14.4 and for all other purposes, Mr Dennis Lin, who retires as a Director by rotation, and being eligible, is re-elected as a Director."

PROXY TYPE	NUMBER	%
For	163,996,473	80.76
Against	36,726,550	18.09
Open-usable	2,333,931	1.15
Abstained	1,089,076	N/A
Total	204,146,030	100



APPROVAL OF ISSUE OF SECURITIES UNDER EMPLOYEE SHARE RIGHTS PLAN

To consider and, if thought fit, to pass the following resolution as an ordinary resolution of the Company:



"That for the purposes of ASX Listing Rule 7.2 (exception 13(b) and for all other purposes, approval is given by the Company to issue Equity Securities under the employee incentive scheme titled Employee Share Rights Plan, on the terms and conditions set out in the Explanatory Statement."

PROXY TYPE	NUMBER	%
For	147,422,232	77.67
Against	40,139,231	21.14
Open-usable	2,255,083	1.19
Abstained	708,884	N/A
Total	190,525,430	100



APPROVAL OF ISSUE OF SHARE RIGHTS TO DIRECTOR - DENNIS LIN

To consider and, if thought fit, to pass the following resolution as an ordinary resolution of the Company:



"That for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue 606,502 Share Rights to Dennis Lin (or his nominee/s) under the Employee Share Rights Plan on the terms and conditions set out in the Explanatory Statement."

PROXY TYPE	NUMBER	%
For	136,612,000	72
Against	50,563,568	26.65
Open-usable	2,553,300	1.35
Abstained	793,351	N/A
Total	190,522,219	100



APPROVAL OF ISSUE OF SHARE RIGHTS TO MANAGING DIRECTOR – KRISTY CARR

To consider and, if thought fit, to pass the following resolution as an ordinary resolution of the Company:



"That for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue 1,091,703 Share Rights to Kristy Carr (or her nominee/s) under the Employee Share Rights Plan on the terms and conditions set out in the Explanatory Statement."

PROXY TYPE	NUMBER	%
For	136,790,621	72.08
Against	50,666,572	26.69
Open-usable	2,326,997	1.23
Abstained	738,029	N/A
Total	190,522,219	100



RATIFICATION OF PRIOR ISSUE OF SHARES

To consider and, if thought fit, to pass the following resolution as an ordinary resolution of the Company:



"That for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the allotment and issue of 63,374,717 Shares to eligible institutional investors, on the terms and conditions set out in the Explanatory Statement."

PROXY TYPE	NUMBER	%
For	158,975,493	87.54
Against	20,288,103	11.17
Open-usable	2,349,731	1.29
Abstained	22,477,680	N/A
Total	204,091,007	100



AMENDMENT TO CONSTITUTION

To consider and, if thought fit, to pass the following resolution as a special resolution of the Company:



"That for the purposes of section 136(2) of the Corporations Act and for all other purposes, approval is given by the Company to amend its Constitution to include new provisions around the use of technology by the Company as set out in item 7 of the Explanatory Statement."

PROXY TYPE	NUMBER	%
For	169,501,957	83.53
Against	30,971,408	15.26
Open-usable	2,468,512	1.21
Abstained	1,204,153	N/A
Total	204,146,030	100



APPOINTMENT OF NEW AUDITOR

To consider and, if thought fit, to pass the following resolution as an ordinary resolution of the Company:



"That, subject to ASIC consent of being received by the Company for Deloitte Touche Tohmatsu to resign as auditor, for the purpose of Section 327B(1)(b) of the Corporations Act and for all other purposes, KPMG, having been nominated by a Shareholder and having consented in writing to act, be appointed as auditor of the Company."

PROXY TYPE	NUMBER	%
For	187,122,047	92.03
Against	13,862,158	6.82
Open-usable	2,336,916	1.15
Abstained	824,909	N/A
Total	204,146,030	100



INCREASE IN NON-EXECUTIVE DIRECTORS' FEE POOL

To consider and, if thought fit, to pass the following resolution as an ordinary resolution of the Company:



"That, for the purposes of clauses 14.7 and 14.8 of the Company's constitution, ASX Listing Rule 10.17, and for all other purposes, approval is given for the Company to increase the total aggregate fixed sum per annum to be paid to non-executive Directors by \$200,000 to no more than \$500,000."

PROXY TYPE	NUMBER	%
For	161,114,187	85.48
Against	25,016,877	13.28
Open-usable	2,334,536	1.24
Abstained	963,860	N/A
Total	189,429,460	100



